Photodynamic therapy: novel third-generation photosensitizers one step closer?
Photodynamic therapy: novel third-generation photosensitizers one step closer?
复制标题
DOI：
10.1038/bjp.2008.98
复制
发表时间：
2008-05-01
影响因子：
7.3
通讯作者：
Boyle, R. W.
中科院分区：
文献类型：
--
作者：
Josefsen, L. B.;Boyle, R. W.
光动力致敏剂是由特定波长的光激活的药物，用于某些疾病的光动力治疗（PDT）。改进PDT性能的第二代和第三代光敏剂目前正在研究中。在本期《英国药理学杂志》上，Leung等人描述了针对HepG2和HT29肿瘤细胞的第二代光敏剂（BAM-SiPc）的合成和研究。bamm - sipc具有选择性的双氨基功能化，并在小动物模型中显示出强大的PDT活性。然而，它也在动物（小小鼠）的多个器官和组织中表现出非选择性分布和积累。这些问题突出了良好的生物分布和定位特性对有效光敏剂的重要性和必要性。肿瘤特异性的缺乏可能对BAM-SiPc在临床PDT中的潜在作用产生重大影响。
Photodynamic sensitizers are drugs activated by light of a specific wavelength and are used in the photodynamic therapy (PDT) of certain diseases. Second- and third-generation photosensitizers with improved PDT properties are now under investigation. In this issue of the British Journal of Pharmacology, Leung et al. have described the synthesis and investigation of a second-generation photosensitizer (BAM-SiPc) targeted towards the cells of HepG2 and HT29 tumours. BAM-SiPc is selectively functionalized with bis-amino groups and has demonstrated potent PDT activity in a small animal model. However, it also exhibited non-selective distribution and accumulation in multiple animal (small mouse) organs and tissue. These issues highlight the importance and need for good biodistribution and localization properties for an efficacious photosensitizer. The lack of tumour specificity may have a significant impact on the potential BAM-SiPc has in clinical PDT.